摘要
目的分析α-干扰素治疗急性呼吸道病毒感染的疗效及其对辅助性T细胞1(T helper cell 1,Th1)/辅助性T细胞2(T helper cell 2,Th2)平衡及肺功能的影响。方法选择2020年12月至2022年12月我院收治的急性呼吸道病毒感染患者79例,分为观察组35例和对照组44例。两组均给予常规对症治疗,对照组采用利巴韦林注射液雾化吸入,观察组采用重组人干扰素α-2b注射液雾化吸入。比较两组临床疗效、治疗后临床症状消失时间;检测治疗前后肺功能指标[用力肺活量(forced vital capacity,FVC)、第一秒用力呼气容积(forced expiratory volume in the first second,FEV_(1))、呼气流量峰值(peak expiratory flow,PEF)],检测Th1、Th2细胞比例并计算Th1/Th2值,检测血清C反应蛋白(C-reactive protein,CRP)、白细胞介素(interleukin-6,IL-6)、肿瘤坏死因子-α(tumor necrosis factor were detected-α,TNF-α)水平。结果观察组治疗总有效31例(88.57%),高于对照组30例(68.18%)(P<0.05);治疗后观察组咽喉疼痛、咳嗽、流涕、退热消失时间为(80.43±11.35)h、(65.28±15.63)h、(35.52±11.24)h、(34.32±8.64)h短于对照组(92.64±15.49)h、(80.47±11.28)h、(57.26±13.44)h、(51.37±10.12)h(P<0.05);观察组治疗后FVC(1.35±0.24)L、FEV_(1)(2.47±0.42)L、PEF(195.32±30.12)L/min高于对照组(1.22±0.18)L、(2.06±0.39)L、(177.58±28.42)L/min(P<0.05);治疗后观察组Th1(11.24±2.08)%、Th1/Th2(1.77±0.53)%高于对照组(9.36±1.55)%、1.35±0.42,观察组Th2(6.33±0.87)%低于对照组(6.92±1.13)%(P<0.05);观察组CRP(8.63±1.95)mg/L、IL-6(34.26±6.51)pg/ml、TNF-α(118.62±9.17)pg/ml低于对照组(14.25±3.76)mg/L、(51.22±9.06)pg/ml、(146.02±11.64)pg/ml(P<0.05)。结论α-干扰素治疗急性呼吸道病毒感染疗效好,有利于促进Th1/Th2细胞平衡,降低CRP、IL-6、TNF-α水平,促进患者肺功能恢复具有临床意义。
Objective To analyze the efficacy ofα-interferon in the treatment of acute respiratory virus infection and its effects on T helper cell 1(Th1)/T helper cell 2(Th2)and lung function.Methods A total of 79 patients with acute respiratory virus infection admitted to North Hospital of Ankang Central Hospital from December 2020 to December 2022 were divided into observation group 35 cases and control group 44 cases using random number table method.Both groups were given routine symptomatic treatment,the control group received nebulized inhalation of ribavirin injection,and the observation group received recombinant human interferonα-2b injection nebulized inhalation.Compare the clinical efficacy and time of symptom disappearance after treatment between the two groups;The pulmonary function indexes[forced vital capacity(FVC),forced expiratory volume in the first second(FEV_(1)),peak expiratory flow(PEF)]before and after treatment were detected,the proportion of Th1 and Th2 cells was detected,and the Th1/Th2 value was calculated.Serum C-reactive protein(CRP),interleukin(IL-6),and tumor necrosis factor were detected-α(TNF-α)Horizontal.Results The total effective rate of the observation group was 31 cases(88.57%),significantly higher than that of the control group 30 cases(68.18%)(P<0.05);After treatment,the disappearance time of throat pain,cough,runny nose,and fever in the observation group was(80.43±11.35)h,(65.28±15.63)h,(35.52±11.24)h,and(34.32±8.64)h,respectively,which were significantly shorter than those in the control group[(92.64±15.49)h,(80.47±11.28)h,(57.26±13.44)h,and(51.37±10.12)h,respectively,P<0.05];After treatment,the FVC,FEV_(1),and PEF in the observation group were(1.35±0.24)L,(2.47±0.42)L,and(195.32±30.12)L/min,respectively,which were significantly higher than those in the control group[(1.22±0.18)L,(2.06±0.39)L,and(177.58±28.42)L/min,respectively,P<0.05];After treatment,the Th1 and Th1/Th2 values in the observation group were(11.24±2.08)%and(1.77±0.53)%,respectively,significantly higher than those in the control group(9.36±1.55)%and(1.35±0.42)%,respectively.The Th2 values in the observation group were(6.33±0.87)%,lower than those in the control group(6.92±1.13)%(P<0.05);Post treatment observation group CRP,IL-6,TNF-αThe levels were(8.63±1.95)mg/L,(34.26±6.51)pg/ml,and(118.62±9.17)pg/ml,respectively,which were significantly lower than those in the control group[(14.25±3.76)mg/L,(51.22±9.06)pg/ml,(146.02±11.64)pg/ml,P<0.05].Conclusionα-Interferon has a good therapeutic effect on acute respiratory virus infection,which is beneficial for promoting Th1/Th2 cell balance and reducing CRP,IL-6,and TNF-αLevel,can promote the recovery of lung function in patients,with high safety.
作者
陈冬丽
邓迎丽
毕婧
Chen Dongli;Deng Yingli;Bi Jing(Department of emergency medicine,North Hospital of Ankang Central Hospital,Ankang 725000,China;First department of respiratory,North Hospital of Ankang Central Hospital,Ankang 725000,China;Second department of respiratory,North Hospital of Ankang Central Hospital,Ankang 725000,China)
出处
《中华肺部疾病杂志（电子版）》
2024年第4期590-594,共5页
Chinese Journal of Lung Diseases(Electronic Edition)
基金
陕西省自然科学基础研究计划(2020JM-394)。
